Bli medlem
Bli medlem

Du är här


Oncology Venture: Subscription Period for Rights Issue in Oncology Venture Sweden AB Begins Today

Today, May 12, 2016, is the first day of the subscription period for
rights issue in Oncology Venture Sweden AB (OV). The rights issue may
also be signed by the public. Subscription period runs through May
26, 2016. Should the rights issue be fully subscribed, it will raise
a capital of 20.7 million SEK before issuing costs. Beforehand, the
company has agreed on subscription commitments amounting to
approximately 13.1 million SEK, which equals about 64% of the rights
issue's total volume. Prospect, teaser and application form can be
downloaded at the respective websites of Oncology Venture
(, AktieTorget ( and
Sedermera Fondkommission (

Rights Issue to Drive Development of The Company's Leading Drug
Candidate, And to Form SPV

Oncology Venture holds the capital to drive development of its two
inlicensed drug candidates APO010 and Irofulven. The aim of capital
raised through the rights issue is first and foremost driving the
development of OV's third drug candidate LiPlaCisTM forwards, through
a proof of concept.

Oncology Venture also intends to create one or more so called "Special
Purpose Vehicles" (SPV) by starting one or more international

The rational behind creating an international subsidiary is to further
extend OV's product pipeline to more than five drug candidates. With
the above mentioned procedure, Oncology Venture intends to test its
most interesting inlicensed drug candidates for more than one
indication. The board of Oncology Venture firmly believes enabling an
extended pipeline by creating one or more SPV's, will increase the
company's market potential. It will also bring additional value to
OV's shareholders by facilitating further financing of drug projects
in the form of direct injection of international private and venture
capital into the projects.

"Oncology Venture is currently in an important development stage. The
work with our drug candidates APO010 and Irofulven proceeds according
to the plan, financed by existing fundings. The now leading drug
candidate LiPlaCisTM was recently inlicensed: a drug for which over
1000 Breast Cancer patients have already undergone the screening
process. LiPlaCisTM is in the final stage of a promising clinical
Phase 1 testing (all indications) and is going towards an extended,
focused and prolonged proof-of-concept studie", says Adjunct
Professor Peter Buhl Jensen, M.D., and CEO of Oncology Venture.

"We have a current pipeline of products we firmly believe in, while at
the same time our ambition is further increasing Oncology Venture's
potential through the planned creation of one or more SPV's. Among
other effects, creating such SPV's will facilitate taking in
international private and venture capital. By doing so, we will get
the possibility to considerably increase the number of drug
candidates in our pipeline, and to investigate several indications
for each drug candidate", Peter Buhl Jensen further comments.

The Offer, Summary

Subscription Period May 12 - 26, 2016

Record Date and Preferential May 3, 2016, was the last trading day for Oncology Venture stock shares including rights of receiving subscription rights.

Excluding rights of receiving subscription rights, the last trading
day was May 4, 2016. Record date was May 6, 2016.

Each currently held stock share qualifies for one (1) subscription
right. Holding seven (7) subscription rights entitles signing two (2)
new stock shares.

Issue Price 10.00 SEK per stock share.

Volume of Issuance Oncology Venture is hereby conducting a rights issue of 20 666 240 SEK, comprising a maximum of 2 066 624 stock shares.

The rights issue is also open to the public.

Subscription Commitments Oncology Venture has received subscription commitments of approximately 13.1 million SEK, which equals cirka 64% of the total volume of issuance.

Number of Shares Before Rights Issue 7 233 186 stock shares.

Valuation (pre-money) Cirka 72,3 million SEK.

Trading in Subscrition Rights Trading in subscrition rights will be done at AktieTorget during the time period May 12-24, 2016.

Trading With Paid Subscribed Shares Trading with paid subscribed shares will be done at AktieTorget as of May 12, 2016, and until Bolagsverket (the Swedish Company Authority) has registrered the rights issue. The registration is expected to be done by the end of June, 2016.

Market Place The Oncology Venture stock shares are registrered at AktieTorget.

Prospect (containing complete conditions and instructions), teaser and
application form are available via the respective websites of
Oncology Venture (, AktieTorget
( and Sedermera Fondkommission (

Investor Events

During the rights issue period, Oncology Venture will partake in
investor events to give information about the company and its future
plans. The investor events are free of charge and refreshments will
be included. For more information on the investor events, please
visit the web page of Sedermera Fondkommission (,
contact Sedermera on the phone, +46 431 47 17 00, or via email:

To sign up for the events, email:

· Stockholm, May 17, 2016, 11.45 am - 1.00 pm, Scandic Hotel Klara.

· Malmö, May 20, 2016, 11.45 am - 1.00 pm, Malmö Börshus, Skeppsbron

Anmälan sker till

· Göteborg, May 23, 2016, 11.45 am - 1.00 pm, Elite Park Avenue
Hotell, Kungsportsavenyen 36.

Anmälan sker till

· Malmö, May 24, 2016 kl. 3.30 pm - 4.00 pm, Aktiespararna, Casino
Cosmopol, Slottsgatan 33.

Sign up for this event at

Financial Advisor

Oncology Venture's financial advisor for the rights issue is Sedermera
Fondkommission .

For questions regarding the rights issue, please contact:

Sedermera Fondkommission

Telephone: +46 431 47 17 00


For more information regarding Oncology Venture, please contact:

Peter Buhl Jensen, CEO

Telephone: +45 21 60 89 22


About Oncology Venture Sweden AB

Oncology Venture Sweden AB is engaged in the research and development
of anti-cancer drugs via its wholly owned Danish subsidiary Oncology
Venture ApS. Oncology Venture holds a license to use Drug Response
Prediction, DRP™, in order to significantly increase the probability
of success in clinical trials. DRP™ has proven its ability to provide
a statistically significant prediction of clinical outcomes from drug
treatment in cancer patients in 29 of the 37 clinical studies that
were examined. The Company uses a model that betters the odds
compared to traditional pharmaceutical development. Instead of
treating all patients with a particular type of cancer, patients are
first screened, and only those who are most likely to respond to the
treatment will be treated. Via a well defined patient group, risks
and costs are reduced and the development process becomes more

Our current product portfolio of Drug Candidates: LiPlaCis, an
intelligent liposomal formulation of cisplatin for Breast Cancer,
Irofulven, developed from a fungus for Prostate Cancer and APO010, an
immuno-oncology product for Multiple Myeloma.


Författare ATORG

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.